Based on the extension of patent protection from 2034 to 2039 and hence both the duration of peak sales and the number of years of cash flow in our forecast, we increase our valuation range to SEK 114-150 (SEK 83-110).
FluoGuide announced that it has acquired exclusive rights to a patent to use FG001 for photothermal therapy, an extension of photodynamic therapy that kills cancer cells with heat. The press release referenced strong preclinical data, and the application is important to justify our drug cost assumptions. The patent extends FluoGuide's IP to 2039 from 2034, materially extending peak sales and cash flows.
LÄS MER